Cargando…
A prognostic model integrating PET‐derived metrics and image texture analyses with clinical risk factors from GOYA
Image texture analysis (radiomics) uses radiographic images to quantify characteristics that may identify tumour heterogeneity and associated patient outcomes. Using fluoro‐deoxy‐glucose positron emission tomography/computed tomography (FDG‐PET/CT)‐derived data, including quantitative metrics, image...
Autores principales: | Kostakoglu, Lale, Dalmasso, Federico, Berchialla, Paola, Pierce, Larry A., Vitolo, Umberto, Martelli, Maurizio, Sehn, Laurie H., Trněný, Marek, Nielsen, Tina G., Bolen, Christopher R., Sahin, Deniz, Lee, Calvin, El‐Galaly, Tarec Christoffer, Mattiello, Federico, Kinahan, Paul E., Chauvie, Stephane |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175666/ https://www.ncbi.nlm.nih.gov/pubmed/35846039 http://dx.doi.org/10.1002/jha2.421 |
Ejemplares similares
-
A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials
por: Kostakoglu, Lale, et al.
Publicado: (2023) -
Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP
por: Procházka, Vít, et al.
Publicado: (2020) -
Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study
por: Kostakoglu, Lale, et al.
Publicado: (2021) -
Pevonedistat, a NEDD8‐activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre‐clinical models of diffuse large B‐cell lymphoma
por: Torka, Pallawi, et al.
Publicado: (2020) -
Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial
por: Phillips, Elizabeth H., et al.
Publicado: (2020)